This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/national-drug-code-directory/
n27http://linked.opendata.cz/resource/AHFS/
n25http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/iuphar/
n11http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01337/identifier/guide-to-pharmacology/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01337
rdf:type
n3:Drug
n3:description
A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
n3:dosage
n21:271B3FD8-363D-11E5-9242-09173F13E4C5 n21:271B3FD9-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1.5 to 2.7 hours.
n3:indication
Used as a muscle relaxant during anesthesia and surgical procedures.
owl:sameAs
n13:DB01337 n28:DB01337
dcterms:title
Pancuronium
adms:identifier
n6:Pancuronium n7:7907 n8:25453 n9:46506118 n14:PA450771 n15:441289 n16:C07551 n17:0703-2812-04 n18:4001 n19:4001 n20:DB01337
n3:mechanismOfAction
Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
n3:packager
n22:271B3FD2-363D-11E5-9242-09173F13E4C5 n22:271B3FD5-363D-11E5-9242-09173F13E4C5 n22:271B3FD3-363D-11E5-9242-09173F13E4C5 n22:271B3FD4-363D-11E5-9242-09173F13E4C5
n3:synonym
Bromure de pancuronium Pancuronium Bromuro de pancuronio
n3:volumeOfDistribution
* 241 to 280 mL/kg
n10:hasAHFSCode
n27:12-20-00
n3:proteinBinding
77 to 91%
n3:salt
n24:hasConcept
n25:M0015813
n3:IUPAC-Name
n4:271B3FDE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3FE4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3FE3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3FE0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3FE1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3FE2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3FF3-363D-11E5-9242-09173F13E4C5 n4:271B3FDC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3FDD-363D-11E5-9242-09173F13E4C5 n4:271B3FDA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3FDB-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:M03AC01
n3:H-Bond-Acceptor-Count
n4:271B3FEA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3FEB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3FE5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3FE6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3FE8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3FE7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3FE9-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:category
n3:clearance
* Plasma cl=1.1–1.9 mL/minute/kg
n3:containedIn
n26:271B3FD6-363D-11E5-9242-09173F13E4C5 n26:271B3FD7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3FEF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3FF1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3FF2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3FF4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3FEE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3FED-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3FF0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3FDF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3FEC-363D-11E5-9242-09173F13E4C5